The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Open accessAbstract
BACKGROUND: , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The phase II portion of KRYSTAL-2 included 116 patients with KRAS G12C NSCLC treated with adagrasib 600 mg bid [100]. All patients had prior platinum-doublet chemotherapy and 98.3% had received both chemotherapy and checkpoint inhibitor therapy. With a median follow-up of 12.9 months, the ORR was 42.9%.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from both CodeBreak 100 for sotorasib and KRYSTAL-1 for adagrasib led to the approval of these inhibitors to treat G12C-mutant NSCLC [51,53,94].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adagrasib, an ORR was 23.0% in CRC, compared to 42.8% in NSCLC (Table 1) [27, 48].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because KRAS mutations are often clonal founder events, mutant KRAS ctDNA can serve as a highly informative molecular marker for tumor burden, treatment response, minimal residual disease, and emergence of resistance [29,47,77,78].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“This subset of patients that were evaluable for longitudinal KRASG12C ctDNA response in Cohort A exhibited a slightly higher ORR (56.4%, 22/39 cycle ctDNA response evaluable) compared to Cohort A overall (50.5%, 48/95 RECIST 1.1 evaluable patients)19”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“Updated data from 116 patients with previously treated NSCLC included in a registrational phase II cohort of KRYSTAL-1 showed an ORR of 42.9%, a DCR of 79.5%, median DoR of 8.5 months, median PFS of 6.5 months, median OS of 12.6 months and estimated 1-year OS of 50.8% with adagrasib83.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [83]
In the citing paper
“While these drugs clearly have clinical activity, overall response rates (30-40%) and disease control (~60%) in NSCLC are modest and transient, with median duration less than one year (9,10).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0–51.8) [100].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Mehta, M. P., Rodrigus, P. T. R., Terhaard, C. H. J., Rao, A. R., Suh, J. H., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M. H., Komaki, R. U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 466
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Research works printed but not linked: 1
- Mirati Therapeutics. U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics’ new drug application for adagrasib as treatment of previously treated KRASG12C-mutated non-small cell lung cancer. February 15 2022 (https://ir.mirati.com/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspx).
Cited by
Sorted by citations
Items 401–500 of 1,002
The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
Andrade, F., German-Cortés, J., Montero, S., Carcavilla, P., Baranda-Martínez-Abascal, D., Moltó‐Abad, M., Seras‐Franzoso, J., Díaz‐Riascos, Z. V., Rafael, D. F. D. S., & Abasolo, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061686 · Cited by 9
KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
Osta, B. E. E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-174 · Cited by 8
Wang, M., Zhang, Y., Wu, S., Zhang, S.-Y., Shan, H.-L., Yang, X., Xu, X., Song, L.-Q., & Qu, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-449 · Cited by 10
Barsouk, A. A., Friedes, C., Iocolano, M., Doucette, A. G., Cohen, R. B., Robinson, K. W., D’Avella, C. A., Marmarelis, M. E., Kosteva, J. A., Singh, A. P., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.12.009 · Cited by 8
Insights into how adeno-squamous transition drives KRAS inhibitor resistance
Hu, F., & Lito, P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.014 · Cited by 8
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Tian, L., Liu, C., Zheng, S., Shi, H., Fang, W., Jiang, W., Dong, Y., Xu, H., Yin, E., Sun, N., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06089-y · Cited by 9
Effective design of therapeutic nanovaccines based on tumor neoantigens
Wang, W., Zhai, Y., Yang, X., Ye, L., Lu, G., Shi, X., & Zhai, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.078 · Cited by 8
Falk, M., Willing, E., Schmidt, S., Schatz, S., Galster, M., Tiemann, M., Ficker, J. H., & Brueckl, W. M. (2023) · Current Oncology · doi:10.3390/curroncol30020130 · Cited by 8
Genomic and transcriptomic insights into the precision treatment of pulmonary enteric adenocarcinoma
Liu, Y., Lü, T., Yuan, M., Chen, R., Lu, J., Wang, H., Wu, Z., & Wang, Y. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.005 · Cited by 8
Hines, J. B., Bowar, B., Levine, E. E., Esposito, A., Garassino, M. C., & Bestvina, C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119429 · Cited by 8
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“This strategy eventually led to the development of sotorasib (AMG510) and adagrasib (MRTX849) [22, 23], which showed remarkable preclinical and clinical efficacy [24 – 27] and subsequently gained accelerated approval in 2021 and 2022 as monotherapy against KRAS G12C NSCLC.”
InfluentialKRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Tang, M., Wu, Y., Bai, X., & Lü, Y. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s473368 · Cited by 7
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer
Higgins, J. P., Carlisle, J. W., Moniri, N. H., Gupta, S., Oduah, E., & Leal, T. A. B. (2024) · Future Oncology · doi:10.1080/14796694.2024.2430172 · Cited by 7
KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
Gelfer, R., Gulla, A., Kalvin, H. L., Song, Y., Harding, J. J., Abou‐Alfa, G. K., O'Reilly, E. M., Park, W., Chandwani, R., Wei, A. C.-C., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00263 · Cited by 9
Ghai, S., Shrestha, R., & Su, K. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1500880 · Cited by 7
Namini, M. T., Bhagya, G., & Sharma, M. (2025) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2025.100073 · Cited by 7
Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine
Maciag, A. E., Yang, Y., Sharma, A. K., Turner, D. M., DeHart, C. J., Abdelkarim, H., Fan, L., Smith, B. P., Kumari, V., Dyba, M. D., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2410766122 · Cited by 7
Zeng, J., Jiang, W., & Wu, L. (2025) · Journal of Translational Research · doi:10.1080/29947448.2024.2427647 · Cited by 7
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
Robinson, H. R., Lakritz, S., Pavlick, D. C., Davis, S. L., Lieu, C. H., Eule, C. J., Graham, L. S., Spiess, P. E., Li, R., Kamat, A. M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105312 · Cited by 8
Chafe, S. C., Zhai, K., Aghaei, N., Miletic, P., Huang, Z., Brown, K. R., Mobilio, D., Young, D. W., Suk, Y., Grewal, S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2459 · Cited by 7
Adagrasib in the treatment of colorectal cancer
Haddad, S. F., Bouferraa, Y., & Nair, K. G. (2025) · Future Oncology · doi:10.1080/14796694.2025.2524311 · Cited by 9
Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D
Budai, B., Vaupel, A., Dickson, C. J., Beyer, K. S., Guthy, D. A., Ostermann, N., McGregor, L. M., de Kanter, R., Weiss, A., Linder, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01214 · Cited by 9
Zhu, Z., Chen, H., Feng, C., Chen, L., Ma, C., Liu, Z., Qu, Z., Bartlett, D. L., Lu, B., Li, K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010514 · Cited by 7
Integrative genomic identification of therapeutic targets for pancreatic cancer
Guo, J. A., Gong, D. H., Evans, K. E., Takahashi, K., Jambhale, A. D., Shiau, C., Yu, P. Z., Wang, S., Wu, W., Chugh, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116191 · Cited by 9
Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
Lim, J. U., Negrao, M. V., & Hong, D. S. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-115849 · Cited by 9
Self-citationClinical Actionability of Genes in Gastrointestinal Tumors
Gonzalez, N. S., Patelli, G., & Crisafulli, G. (2025) · Genes · doi:10.3390/genes16101130 · Cited by 7
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Stern, Y. E., Ghosh, P., Peroza, J., Solanki, H. S., Imbody, D. J., Bridenstine, L., Pandurangan, T., Frydman, S. M., Nickens, K. N., Walker-Mimms, H. L., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0450 · Cited by 7
Cho, D., Shin, K., Hong, T. H., Lee, S. H., Kim, Y.-H., Kim, I.-H., Hong, S. H., Lee, M. A., & Park, S. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210908 · Cited by 7
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
Lim, S.-A., Todd, H., Goodhart, G., Chang, W.-H., Amparo, A. M., Bridgens, R., Dilly, J., Park, S. J., Beal, R. M., Shehadeh, S. M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1835 · Cited by 10
Identification and characterization of binders to a cryptic and functional pocket in KRAS
Beyer, K. S., Klein, J., Katz, S., Welker, P., Lanter, M., Guthy, D. A., Pollehn, K., Gluck-Gadé, A., Bleu, M., Desogus, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65844-3 · Cited by 7
Mulero‐Sánchez, A., Bosma, A. R., Visuvasam, B., Pouliopoulou, N., van de Ven, M., Proost, N., Boeije, M., Lieftink, C., Beijersbergen, R. L., Bernards, R., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03616-z · Cited by 7
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
Endres, N., Do, S., Mroue, R. M., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., (1471192), J. C. T., Nguyen, L. K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02272 · Cited by 8
Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
Peng, X., Xia, Z., Guo, Y. S., & Li, Y. (2023) · Aging · doi:10.18632/aging.204770 · Cited by 7
Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer
Yang, W., Gong, D.-H., Wu, H., Gao, Y., & Hao, G. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103705 · Cited by 7
Broeker, C. D., Ortiz, M. M. O., Murillo, M. S., & Andrechek, E. R. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01723-3 · Cited by 7
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors
Kareff, S. A., Trabolsi, A., Krause, H. B., Samec, T., Elliott, A., Rodríguez, E., Olazagasti, C., Watson, D. C., Bustos, M. A., Hoon, D. S. �., et al. (2024) · Cancers · doi:10.3390/cancers16081572 · Cited by 7
Prevention of Brain Metastases: A New Frontier
Pellerino, A., Davidson, T. M., Bellur, S. S., Ahluwalia, M. S., Tawbi, H. A., Rudà, R., & Soffietti, R. (2024) · Cancers · doi:10.3390/cancers16112134 · Cited by 8
Erhart, C.-C., Cefalì, M., Mangan, D., Kasenda, B., & Wannesson, L. (2024) · Swiss Medical Weekly · doi:10.57187/s.3695 · Cited by 7
Tajiknia, V., Pinho-Schwermann, M. P., Srinivasan, P. R., Borrero, L. J. H., Zhang, L., Huntington, K. E., & El‐Deiry, W. S. (2024) · American Journal of Cancer Research · doi:10.62347/dvxl1377 · Cited by 8
Advances in the Management of Lung Cancer Brain Metastases
Hockemeyer, K., Rusthoven, C. G., & Pike, L. (2024) · Cancers · doi:10.3390/cancers16223780 · Cited by 10
Warnecke, B., & Nagasaka, M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s466217 · Cited by 7
von Itzstein, M. S., Burns, T. F., Dowell, J. E., Horn, L., Camidge, D. R., York, S. J., Eaton, K. D., Kyle, K., Fattah, F. J., Liu, J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1722 · Cited by 7
Jameson, N. M., Kim, D., Lee, C., Skrable, B., Shea, A., Guo, X., Izadi, H., Abed, M., Harismendy, O., Ma, J., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0411 · Cited by 7
Liu, Y., Gao, Y. J., Wang, Y., Zhao, C., Zhang, Z., Li, B., & Zhang, T. (2022) · BMC Cancer · doi:10.1186/s12885-022-10236-9 · Cited by 7
Knetki‐Wróblewska, M., Tabor, S., Płużański, A., Lewandowska, Z., Tysarowski, A., Pawlik, H., Kowalski, D. M., & Krzakowski, M. J. (2022) · Current Oncology · doi:10.3390/curroncol30010037 · Cited by 7
With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors
Mainardi, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100950 · Cited by 8
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
Cheema, P. K., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Sacher, A. G., Sheffield, B. S., Snow, S. L., Vincent, M. D., et al. (2023) · Current Oncology · doi:10.3390/curroncol30070476 · Cited by 10
Setting the Benchmark for KRAS G12C -Mutated NSCLC
Passaro, A., & Peters, S. (2022) · New England Journal of Medicine · doi:10.1056/nejme2207902 · Cited by 7
The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
Murciano‐Goroff, Y. R., & Lito, P. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00676-4 · Cited by 8
Daley, B. R., Sealover, N. E., Sheffels, E., Hughes, J. M., Gerlach, D., Hofmann, M. H., Kostyrko, K., Mair, B., Linke, A. J., Beckley, Z., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.07.570642 · Cited by 7
Müller, M., & Tougeron, D. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-1629 · Cited by 7
Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.640711 · Cited by 7
Prajapati, V., Singh, A. K., Kumar, A. M., Singh, H., Pathak, P., Grishina, M., Kumar, V., Khalilullah, H., Verma, A., & Kumar, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00923a · Cited by 6
Chopra, D., Lan, Z., Waterhouse, D. M., Wolf, J., Felip, E., Moradian, H., Karim, N., Obiozor, C. C., & Stollenwerk, B. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03259-8 · Cited by 7
Barrambana, S., Zamorano-Domínguez, E., Liaki, V., & Guerra, C. E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115652 · Cited by 8
Li, H., Liu, C., Zheng, S., Wu, P., Xu, H., Hao, X., Li, J., Xing, P., Duan, J., Wang, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102235 · Cited by 6
Dian, M., Yun, L., Meng, Q., Lin, S., Ji, M., Zhou, Y., Liu, W., Yang, Z., Zhao, Y., Li, G., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07980-8 · Cited by 6
Wang, L., Chen, X., Qu, R., Shao, S., Gong, L., Li, T., Jiang, S., Lu, Y., Ma, Y., Sun, Y. N., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218013 · Cited by 7
Liquid Biopsy in Lung Cancer: Tracking Resistance to Targeted Therapies
Urtecho, S. B., Munárriz, B., Rabey, M. R., & Leighl, N. B. (2025) · Cancers · doi:10.3390/cancers17213474 · Cited by 8
Alanazi, F. E., Alatawi, Y. M., Alattar, A., Alshaman, R., Kotb, A. A., & Hetta, . F. (2025) · Pharmaceuticals · doi:10.3390/ph18121788 · Cited by 8
Wei, X., Blaj, C., Al-Radhawi, M. A., Lai, L., Maldonato, B. J., Yang, Y. C., Seu, L., Gundlapalli, H., Jiang, L., Ayala, M. A. M., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1616 · Cited by 6
Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution
Алексахина, С. Н., Ivantsov, A. O., & Имянитов, Е. Н. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074094 · Cited by 6
Chour, A., Basse, C., Lebossé, F., Bonté, P., Girard, N., & Duruisseaux, M. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107789 · Cited by 7
Wang, K., Zhou, Z., Ma, X., Xu, J., Xu, W., Zhou, G., Zhou, C., Li, H., Zheng, M., Zhang, S., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129780 · Cited by 6
Wu, L., Xu, M., Li, X., Aierken, D., Yu, J., & Qin, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1418469 · Cited by 6
Hung, L., Huang, C., Tung, K.-C., Chen, J., Huang, W., Hsu, C., Fang, Y., Wang, C., Liu, P., Yeh, K., et al. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.09.001 · Cited by 6
Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer
Nakhchi, B. G., Kosuru, R., & Chrzanowska‐Wodnicka, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189853 · Cited by 7
Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
Luo, F., & Arter, Z. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s490942 · Cited by 6
Jiang, Q., Wei, Z., Liu, P., Li, Z., Jiang, H., Cao, Y., Zhang, B., Yan, Y., & He, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1500686 · Cited by 6
Discovery of Small Molecules that Bind to Son of Sevenless 2 (SOS2)
Żak, K. M., Waterson, A. G., Geist, L., Braun, N., Hauer, K., Rumpel, K., Ramharter, J., Stadtmueller, H., Wolkerstorfer, B., Schönbauer, D., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02007 · Cited by 6
IRE1 is a promising therapeutic target in pancreatic cancer
Lucas, D., Sarkar, T., Niemeyer, C. Y., Harnoss, J. C., Schneider, M., Strowitzki, M. J., & Harnoss, J. M. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00551.2024 · Cited by 7
Ito, M., Miyata, Y., Hirano, S., Morihara, N., Takemoto, M., Irisuna, F., Kushitani, K., Suda, K., Soh, J., Takeshima, Y., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02187-y · Cited by 6
Systemic Kras ablation disrupts myeloid cell homeostasis in adult mice
Zamorano-Domínguez, E., Morales-Cacho, L., Barrero, R., Jiménez-Parrado, S., Dhawahir, A., Hernández-Porras, I., Simón-Carrasco, L., Barrambana, S., Sun, P., Galván-del-Rey, A., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2512404122 · Cited by 6
Swart, E. M., Noordhof, A. L., Damhuis, R. A. M., Kunst, P. W. A., Ruysscher, D. D., Hendriks, L. E. L., van Geffen, W. H., & Aarts, M. J. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107290 · Cited by 6
Saltos, A. N., Creelan, B., Tanvetyanon, T., Chiappori, A., Antonia, S. J., Shafique, M. R., Ugrenovic-Petrovic, M., Sansil, S. S., Neuger, A. M., Özakıncı, H., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107313 · Cited by 6
Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer
Lim, S. M., Lee, J. B., Oya, Y., Nützinger, J., & Soo, R. A. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00273 · Cited by 6
Fujimoto, K., Ikeda, S., Tabata, E., Kaneko, T., Sagawa, S., Yamada, C., Kumagai, K., Fukushima, T., Haga, S., Watanabe, M., et al. (2024) · Cancers · doi:10.3390/cancers16071327 · Cited by 7
CodeBreak 200: study limitations, and future directions
Alharbi, M., Awidi, M. A., & Dy, G. K. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1477 · Cited by 6
Comprehensive genomic profiling of over 10,000 advanced solid tumors
Jean–Paul De La, O., Hoag, J. R., Deem, A. K., Wang, M., Starodynov, A., Udhane, S. S., Lobello, J. R., Therala, N., Hall, D. W., Basu, G. D., et al. (2025) · Oncotarget · doi:10.18632/oncotarget.28757 · Cited by 5
Bharadwaj, S., Mierzwicka, J. M., Vaňková, L., & Malý, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02410-w · Cited by 7
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6
Huang, H.-C., Deng, Q., Guo, L., Gorría, T., Pecci, F., Yang, D., Rodig, S. J., Casas, L. E. D. L., Hallin, J. F., Christensen, J. G., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adq6647 · Cited by 7
Self-citationTreating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 4
Xu, X., Chen, X., Xu, R., Huo, Z., Li, C., Nowsheen, S., Aziz, K., Yao, F., Lou, Z., & Deng, M. (2026) · Nature Communications · doi:10.1038/s41467-026-69695-4 · Cited by 6
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 6
Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics
Grochot, R. M., Bartolini, M., Algaze, S. D., Reimann, P., Winder, T., Lenz, H., & Fontana, E. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516576 · Cited by 5
Farnesylation-driven KRAS phase separation promotes colon tumor growth
Wang, X., Zhang, Y., Lu, M., Gong, Y., Guan, T., Hou, G., Wei, Y., Wang, M., Liu, H., Huang, L., et al. (2026) · Cell · doi:10.1016/j.cell.2026.05.002 · Cited by 5
Rosas, D., Barad, P., Wright, J., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146455 · Cited by 5
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
Arbour, K. C., Punekar, S. R., Luo, J., Johnson, M., Spira, A. I., Herzberg, B., Starodub, A., Sommerhalder, D., Hecht, J. R., Garrido‐Laguna, I., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2504059 · Cited by 5
Self-citationChung, C., & Umoru, G. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241242684 · Cited by 5
Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma
Lee, J. J., & Yeh, J. J. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.04.001 · Cited by 5
Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
Dang, S., Zhang, S., Zhao, J., & Li, W. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03449-8 · Cited by 7
Varona, M., Dobson, D. P., Napolitano, J. G., Thomas, R., Ochoa, J. L., Russell, D. J., & Crittenden, C. M. (2024) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.4c00103 · Cited by 5
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer
Wang, H., Lin, L., Liang, C., Pang, J., Yin, J. C., Zhang, J., Shao, Y., Sun, C., & Guo, R. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00520 · Cited by 5
Self-citationPhotonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19
Si, Q., Bai, M., Wang, X., Wang, T., & Qin, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420463 · Cited by 5
KRas plays a negative role in regulating IDO1 expression
Peng, X., Lee, E., liang, J., Colon, T. M., Tran, F., Choi, B. H., & Dai, W. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102167 · Cited by 5
Lee, A. T., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s492126 · Cited by 5
Torresan, S., Bortolot, M., Carlo, E. D., Bertoli, E., Stanzione, B., Conte, A. D., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020554 · Cited by 6
Özilhan, S. E., Efil, S. C., Çanakçı, D., Ağaçkıran, Y., Dede, D. Ş., Kandemir, N. O., Doğan, M., Ünal, T., Kıran, M. M., Kayaçetin, S., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020121 · Cited by 5
Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization
Jaidee, R., Jusakul, A., Pocasap, P., Kukongviriyapan, V., Senggunprai, L., Prawan, A., Loilome, W., Titapun, A., Jareanrat, A., Thanasukarn, V., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-93192-1 · Cited by 5
Metadata
- Authors
- Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., Bazhenova, L., Negrao, M. V., Pennell, N. A., Zhang, J., Anderes, K., Der-Torossian, H., Kheoh, T., Velastegui, K., Yan, X., Christensen, J. G., Chao, R. C., & Spira, A. I.
- Affiliations
- From the Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) — both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) — all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) — all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at...
- Roswell Park Comprehensive Cancer Center (US)
- ORCID
- Riely, Gregory J.
- Gadgeel, Shirish M.
- Heist, Rebecca S.
- Ou, Sai-Hong I.
- Johnson, Melissa L.
- Sabari, Joshua K.
- Leventakos, Konstantinos
- Yau, Edwin
- Bazhenova, Lyudmila
- Negrao, Marcelo V.
- Pennell, Nathan A.
- Zhang, Jun
- Anderes, Kenna
- Kheoh, Thian
- Velastegui, Karen
- Christensen, James G.
- Chao, Richard C.
- Spira, Alexander I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-14
- Volume
- 387
- Issue
- 2
- Pages
- 120-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281650778
- Cited by
- 1,061
- References
- 27
- Citations by year
- 2026: 247 · 2025: 270 · 2024: 285 · 2023: 203 · 2022: 56
- FWCI
- 131.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mirati Therapeutics, Inc.
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- adagrasib, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, central nervous system metastasis, treatment-related adverse events, previously treated patients
- MeSH terms
- Acetonitriles, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyrimidines, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
